BioSpace
Replimune’s resubmission for RP1 for melanoma comes amid the departures of FDA leaders in place at the time of the drug’s first two rejections, last summer and again in April.
BioSpace
Replimune's resubmission for RP1 for melanoma comes amid the departures of FDA leaders in place at the time of the drug's first two rejections, last summer and again in April.
BioSpace
Replimune’s resubmission for RP1 for melanoma comes amid the departures of FDA leaders in place at the time of the drug’s first two rejections, last summer and again in April.